LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Could Screen for Changes in Proteins Prior to Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 23 Nov 2022
Image: A blood test for people with high risk of breast cancer could diagnose the disease at early stage (Photo courtesy of Pexels)
Image: A blood test for people with high risk of breast cancer could diagnose the disease at early stage (Photo courtesy of Pexels)

Researchers have found changes in the levels of particular proteins in people’s blood up to two years before they were diagnosed with breast cancer. The study could form the basis of blood testing for people with a genetic predisposition or a family history of breast cancer to ensure the disease is diagnosed early when the chances of survival are greatest.

The findings by researchers from Leiden University Medical Center (Leiden, The Netherlands) are from the Trial Early Serum Test Breast cancer (TESTBREAST) study. The study was initiated in 2011 and currently includes 1174 women who are at a high risk of breast cancer, due to their family history or because they carry gene variants that are known to raise their breast cancer risk. The women are being cared for at nine hospitals across The Netherlands where they are offered breast screening at a younger age and more regularly than the rest of the Dutch population who have an average risk of breast cancer. The study has been running for ten years and the women taking part have been giving blood samples at least once a year when they go for screening. Any who develop breast cancer also give samples at the time of diagnosis.

Researchers used a well-established technique called mass spectrometry to analyze the levels of different proteins in the women’s blood. They looked both for variation between different women and changes that emerge in individual women over time. So far, the researchers have made detailed analyses of 30 blood samples taken over time from three women who have been diagnosed with breast cancer and three women who have not developed breast cancer, and found distinct differences between the women over time. This has revealed a set of six proteins that were at higher or lower levels one to two years prior to diagnosis. The researchers will now validate their findings in a larger group of women with and without breast cancer taking part in the TESTBREAST study and in women taking part in other high-risk breast cancer research studies.

“These proteins could form the basis for a blood test for early detection of breast cancer in women at a higher risk. It’s important to note that we found more variation in the protein levels in the blood samples between women, compared to over time within the same woman who developed breast cancer. This shows that testing should probably be based both on proteins that differ between women with and without breast cancer and on proteins that alter in an individual person over time,” said Ms Sophie Hagenaars from Leiden University Medical Center. “If further research validates our findings, this testing could be used as an add-on to existing screening techniques. Blood tests are relatively simple and not particularly painful for most people, so people could be offered screening as often as needed.”

Related Links:
Leiden University Medical Center

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Capillary Blood Collection Tube
IMPROMINI M3

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more